Aug 4, 2020
CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10
Jul 28, 2020
CorMedix Announces Pricing of $20M Public Offering of Common Stock
Jul 27, 2020
CorMedix Announces Proposed Public Offering of Common Stock
Jul 8, 2020
CORMEDIX INC. REPORTS SUBMISSION OF DEFENCATH™ NEW DRUG APPLICATION
May 11, 2020
CORMEDIX INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 11, 2020
CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER
May 6, 2020
CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®
Apr 22, 2020
CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program
Mar 17, 2020
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Mar 6, 2020
CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16
Feb 3, 2020
CORMEDIX APPROVED TO SELL $5.5 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Feb 3, 2020
CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application
Nov 14, 2019
CORMEDIX INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 6, 2019
CorMedix Inc. Announces a Change to its Senior Leadership
Oct 21, 2019
CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA
Sep 30, 2019
CORMEDIX INC. ANNOUNCES EXERCISES OF OUTSTANDING WARRANTS
Aug 15, 2019
CORMEDIX INC. ANNOUNCES EXCHANGE AGREEMENT WITH ITS LARGEST INVESTOR
Jul 17, 2019
CORMEDIX PRESENTS AT FDA PUBLIC MEETING ON THE LIMITED POPULATION PATHWAY FOR ANTIBACTERIAL AND ANTIFUNGAL DRUGS
Jul 9, 2019
CORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN® LOCK-IT-100 DATA
Jul 8, 2019
CORMEDIX ANNOUNCES PUBLICATION OF TAUROLIDINE PRE-CLINICAL ONCOLOGY DATA IN “INVESTIGATIONAL NEW DRUGS” JOURNAL
